<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960946</url>
  </required_header>
  <id_info>
    <org_study_id>2015P0023402</org_study_id>
    <secondary_id>K23HL116780</secondary_id>
    <nct_id>NCT01960946</nct_id>
  </id_info>
  <brief_title>Galectin-3 Blockade in Patients With High Blood Pressure</brief_title>
  <official_title>Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate if Modified Citrus Pectin (MCP) can help people with high blood&#xD;
      pressure. MCP is a dietary supplement that is derived from plants, and therefore is not&#xD;
      subject to approval by the U.S. Food and Drug Administration (FDA). However, MCP has been&#xD;
      deemed as 'generally regarded as safe' by the FDA.&#xD;
&#xD;
      This study will examine whether Modified Citrus Pectin (MCP) can help people with high blood&#xD;
      pressure. The study will help understand how MCP may affect the risk for heart disease in&#xD;
      patients with high blood pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gal-3 appears to be a potential mediator of cardiac fibrosis, preceding the development of&#xD;
      clinical heart failure. In this study, we seek to identify individuals at risk for the&#xD;
      development of heart failure based on clinical hypertension and elevated Gal-3&#xD;
      concentrations. Participants will be randomized to receive a Gal-3 inhibitor (MCP) or&#xD;
      placebo. The primary outcome will be the effect on collagen metabolism, and secondary&#xD;
      outcomes include echocardiographic measures of cardiac structure and function, and&#xD;
      non-invasive measures of vascular function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">August 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in markers of collagen metabolism</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Primary aim will be change in markers of collagen metabolism (PICP, PIIICP, ICTP, TIMP-1) in MCP versus placebo groups over 6 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in galectin-3 level</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in galectin-3 level from baseline until 6 months will be compared between MCP and placebo groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cardiac structure and function</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Changes in cardiac structure and function will be examined using 2-D echocardiography and tissue Doppler imaging. This will include changes in left ventricular mass, dimensions, left atrial size, and left ventricular diastolic function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in arterial stiffness</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>We will examine changes in arterial stiffness (including augmentation index, carotid-femoral pulse-wave velocity) from baseline to 6 months in the MCP and placebo groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Modified Citrus Pectin (MCP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo 5 grams by mouth three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Modified Citrus Pectin (MCP) vs placebo</intervention_name>
    <description>5 grams by mouth three times a day</description>
    <arm_group_label>Modified Citrus Pectin (MCP)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>MCP</other_name>
    <other_name>PectaSol-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21-70 years&#xD;
&#xD;
          -  Physician diagnosed hypertension on stable therapy for 3 months&#xD;
&#xD;
          -  Elevated galectin-3 level (above sex-specific median based on Framingham Heart Study&#xD;
             measures)&#xD;
&#xD;
          -  Able to understand the protocol and provide informed consent in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as systolic blood pressure &gt; 170mmHg, diastolic&#xD;
             blood pressure &gt; 100mmHg&#xD;
&#xD;
          -  Evidence of secondary hypertension&#xD;
&#xD;
          -  History of heart failure, coronary artery disease, stroke, atrial fibrillation&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 45% on echocardiography&#xD;
&#xD;
          -  Use of aldosterone antagonists&#xD;
&#xD;
          -  History of liver cirrhosis&#xD;
&#xD;
          -  History of pulmonary fibrosis&#xD;
&#xD;
          -  Kidney dysfunction, defined as estimated glomerular filtration rate &lt; 45 ml/min/1.73m2&#xD;
&#xD;
          -  Anemia, defined as hematocrit &lt; 37% in men and &lt; 34% in women&#xD;
&#xD;
          -  Use of chelating agents&#xD;
&#xD;
          -  History of Active cancer or malignancy&#xD;
&#xD;
          -  Known pregnancy, those unwilling to avoid pregnancy during the course of the study, or&#xD;
             women currently breastfeeding&#xD;
&#xD;
          -  Hyperkalemia on screening labs, defined as potassium &gt;5.2&#xD;
&#xD;
          -  Anticipated inability to complete or comply with study protocol&#xD;
&#xD;
          -  History of angioedema&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer E Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, López B, Díez J, Wang TJ, Ho JE. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. JACC Basic Transl Sci. 2021 Jan 6;6(1):12-21. doi: 10.1016/j.jacbts.2020.10.006. eCollection 2021 Jan.</citation>
    <PMID>33532663</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jennifer En-Sian Ho M.D.</investigator_full_name>
    <investigator_title>Assistant in Medicine</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Galectin 3</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Vascular Stiffness</keyword>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

